logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 8 of 8 Items
Showing 1 - 8 of 8 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Prediction of visceral leishmaniasis development in a highly exposed HIV cohort in Ethiopia based on Leishmania infection markers: results from the PreLeisH study

van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H,  et al.
2024-12-01 • EBioMedicine
2024-12-01 • EBioMedicine

BACKGROUND

Tar...

Journal Article
|
Research

A preliminary indication that HLA-A*03:01 may be associated with visceral leishmaniasis development in people living with HIV in Ethiopia

de Vrij N, Vandoren R, Ramadan K, Van Hul A, Ceulemans A,  et al.
2024-09-30 • PLOS Neglected Tropical Diseases
2024-09-30 • PLOS Neglected Tropical Diseases

Human immunodeficiency virus (HIV) co-infection is a major challenge for visceral leishmaniasis (VL) control, particularly in Ethiopia where the incidence of both pathogens is high. V...

Journal Article
|
Research

Chronic high-level parasitemia in HIV-infected individuals with or without visceral leishmaniasis in an endemic area in Northwest Ethiopia: Potential superspreaders?

van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H,  et al.
2024-07-19 • Clinical Infectious Diseases
2024-07-19 • Clinical Infectious Diseases

Background

People with human immunodeficiency virus (PWH) with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas wi...

Journal Article
|
Research

Persistent T cell unresponsiveness associated with chronic visceral leishmaniasis in HIV-coinfected patients

de Vrij N, Pollmann J, Rezende AM, Ibarra-Meneses AV, Pham TT,  et al.
2024-05-03 • Communications Biology
2024-05-03 • Communications Biology
A large proportion of HIV-coinfected visceral leishmaniasis (VL-HIV) patients exhibit chronic disease with frequent VL recurrence. However, knowledge on immunological determinants underl...
Journal Article
|
Pre-Print

HLA-A*03:01 is associated with visceral leishmaniasis development in people living with HIV in Ethiopia

de Vrij N, Vandoren R, Ramadan K, Van Hul A, Kassa M,  et al.
2024-02-18 • medRxiv
2024-02-18 • medRxiv
Human immunodeficiency virus (HIV) co-infection is a major challenge for visceral leishmaniasis (VL) control, particularly in Ethiopia where the incidence of both pathogens is high. VL-H...
Journal Article
|
Case Report/Series

Chronic high level parasitemia in HIV-infected individuals with or without visceral leishmaniasis in an endemic area in North-West Ethiopia: potential superspreaders?

van Griensven J, van Henten S, Kibret A, Kassa M, Beyene H,  et al.
2024-01-09 • Clinical Infectious Diseases
2024-01-09 • Clinical Infectious Diseases
BACKGROUND
HIV patients with recurrent visceral leishmaniasis (VL) could potentially drive Leishmania transmission in areas with anthroponotic transmission such as East-Africa, but s...
Journal Article
|
Research

A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia

Diro EGJ, Blesson S, Edwards T, Koert R, Ritmeijer KKD,  et al.
2019-01-17 • PLOS Neglected Tropical Diseases
2019-01-17 • PLOS Neglected Tropical Diseases
BACKGROUND
Visceral leishmaniasis (VL) in human immunodeficiency virus (HIV) co-infected patients requires special case management. AmBisome monotherapy at 40 mg/kg is recommended by...
Journal Article
|
Research

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia

Diro EGJ, Edwards T, Ritmeijer KKD, Fikre H, Abongomera C,  et al.
2019-02-21 • PLOS Neglected Tropical Diseases
2019-02-21 • PLOS Neglected Tropical Diseases
BACKGROUND:
The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is ...